Thomas Obermeyer

From:

Nault, Richard L (HSS) [richard.nault@alaska.gov]

Sent:

Friday, December 03, 2010 9:22 AM

To: Cc: Thomas Obermeyer

Subject:

Toner, Stacy B (HSS)

Attachments:

RE: Mental health parity bill - definitions for 27-LS0081VA

Substance Abuse Dependence.pdf

Mr. Obermeyer,

Please find attached scanned pages of the DSM IV TR manual. You will note that pages 191 to 201 provide an overview of substance abuse disorders and subsequent pages list all of the various substance specific diagnoses. My approach was to, perhaps, provide more information than might be needed rather than less.

Do not hesitate to contact me if I can provide additional information,

Richard

DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS

FOURTH EDITION

DSM-IV-TR

ue to . . .

he individual's nce involves a in the child's

/ findings that nedical condi-

ter (including

ium.

ocial, becupa-

trol as evi-

indifference

buve sub-

ical picture

e.g., 310.f dical condis:

iled

dablished I medical a General ures)

g. 293.9 general

Substance-Related Disorders

he Substance-Related Disorders include disorders related to the taking of a drug of abuse (including alcohol), to the side effects of a medication, and to toxin exposure. In this manual, the term substance can refer to a drug of abuse, a medication, or a toxin. The substances discussed in this section are grouped into 11 classes: alcohol; amphetamine or similarly acting sympathomimetics, caffeine; cannabis; cocaine; hallucinogens; inhalants; ricotine; opioids; phencyclidine (PCP) or similarly acting arylcyclohexylamines; and sectatives, hypnotics, or anxiolytics. Although these 11 classes appear in alphabetical order, the following classes share similar features: alcohol shares features with the sectatives, hypnotics, and anxiolytics; and cocaine shares features with amphetamines or similarly acting sympathomimetics. Also included in this section are Polysubstance Dependence and Other or Unknown Substance-Related Disorders (which include most disorders related to medications or toxins).

Many prescribed and over-the-counter medications can also cause Substance-Related Disorders. Symptoms generally occur at high doses of the medication and usually disappear when the dosage is lowered or the medication is stopped. Medications that may cause Substance-Related Disorders include, but are not limited to, anesthetics and analgesics, anticholinergic agents, anticonvulsants, antihistamines, antihypertensive and cardiovascular medications, antimicrobial medications, antiparkinsonian medications, chemotherapeutic agents, corticosteroids, gastrointestinal medications, muscle relaxants, nonsteroidal anti-inflammatory medications, other over-the-counter medications, antidepressent medications, and disulfuram.

Exposure to a wide range of other chemical substances can also lead to the development of a Substance-Related Disorder. Toxic substances that may cause Substance-Related Disorders include, but are not limited to, heavy metals (e.g., lead or aluminum), rat poisons containing strychnine, pesticides containing nicotine, or acetylcholinesterase inhibitors, nerve gases, ethylene glycol (antifreeze), carbon monoxide, and carbon dioxide. The volatile substances (e.g., fuel, paint) are classified as "inhalants" (see p. 257) if they are used for the purpose of becoming intoxicated; they are considered "toxias" if exposure is accidental or part of intentional poisoning. Impairments in cognition or mood are the most common symptoms associated with toxic substances, although anxiety, hallucinations, delusions, or seizures can also result. Symptoms usually disappear when the individual is no longer exposed to the substance, but resolution of symptoms can take weeks or months and may require treatment.

The Substance-Related Disorders are divided into two groups: the Substance Use Disorders (Substance Dependence and Substance Abuse) and the Substance-Induced Disorders (Substance Intoxication, Substance Withdrawal, Substance-Induced Delirium, Substance-Induced Persisting Dementia, Substance-Induced Persisting Am-



nestic Disorder, Substance-Induced Psychotic Disorder, Substance-Induced Mood

Substance Dependence

Features

The essential feature of Substance Dependence is a cluster of cognitive, behavioral, and physiological symptoms indicating that the individual continues use of the substance despite significant substance-related problems. There is a pattern of repeated self-administration that can result in tolerance, withdrawal, and compulsive drugtaking behavior. A diagnosis of Substance Dependence can be applied to every class of substances except caffeine. The symptoms of Dependence are similar across the various categories of substances, but for certain classes some symptoms are less salient, and in a few instances not all symptoms apply (e.g., withdrawal symptoms are not specified for Hallucinogen Dependence). Although not specifically listed as a criterion item, "craving" (a strong subjective drive to use the substance) is likely to be experienced by most (if not all) individuals with Substance Dependence. Dependence is defined as a cluster of three or more of the symptoms listed below occurring at any time in the same 12-month period.

Tolerance (Criterion 1) is the need for greatly increased amounts of the substance to achieve intoxication (or the desired effect) or a markedly diminished effect with continued use of the same amount of the substance. The degree to which tolerance develops varies greatly across substances. Furthermore, for a specific drug, varied degrees of tolerance may develop for its different central nervous system effects. For example, for opioids, tolerance to respiratory depression and tolerance to analgesia develop at different rates. Individuals with heavy use of opioids and stimulants can

mulants can to analgesia effects. For bathev Buil h tolerance effect with astrones a

Yne te gairi and puadace likely to be ted as a catmptoms are es sest ore r across the every class -grup aviel of repeated -due out to: **Dehavioral**,

e diagnoses Substanceto suopoes : text and cri-Lyear prevgmiteothai t ted that the ntoxication, zed by class procedures impairment ruseurs couwal that are text and crial DysfuncbooM beau

a Disorders

Substance Dependence

NAI N	WI d		-		,					
		W W W A	¥	z ż	×.	•	•	>		Polysub- stance
								v.		anxiolytics
									£	Sedatives, hypnotics,
		74	17	8	e vieta	*	×	×		dine
W.I	WI	ū					×	*	×	Phencycli-
	* -				المستهد	;	¢ >	; ×	×	Oploids.
	- ب				استها	×	Š		×	Nicotine
ur'	 ,				1 = 1	×	>	×	' %&	Inhalants
	,	****	مون		استيار		K	:		gens
							>	×	×	Hallucino-
	ŧ				V ive	:	د <u>چ</u>	×	×	Cocaine
	; -				نهنيد.	*	⋞ >	;	*	Cannabis
S¥.	۔ ۔				iliyer.		Κ >	4		Caffeine
	_						×			amines
						;	>	×	×	Amphet-
٠					₹ 5	×	< 3	>	*	Alcohol
N.	š	~	ינר	W	1	×	×	acuae	dence	
	i	tia Disorder		Delirium	Delirium	with- drawai	Intoxica-		Depen-	
		Amnestic		With-	Intoxica-	من مستخبرة المستحب			0,00	Japie 1.
1 72	Mood Disorders WV	Psychotic Disorders I/W	Psychotic Disorders I/W	Amnestic Psychotic Dementia Disorder Disorders P P IM	Amnestic Psychotic Dementia Disorder Disorders P P W	Amnestic Psychotic Dementia Disorder Disorders P P W	Amnestic Psychotic Dementia Disorder Disorders P P W	Amnestic Psychotic Dementia Disorder Disorders P P W	Amnestic Psychotic Dementia Disorder Disorders P P W	loses associated with class of substances Intoxica- with tion drawal perioder Disorders Abuse tion drawal Delirium Delirium Dementia Disorder Disorders ** * * * * * * * * * * * * * * * * *

develop substantial (e.g., 10-fold) levels of tolerance, often to a dosage that would be leftal to a nonuser. Alcohol tolerance can also be pronounced, but is usually less extreme than for amphetamine. Many individuals who smoke cigarettes consume more than 20 cigarettes a day, an amount that would have produced symptoms of toxicit when they first started smoking. Individuals with heavy use of cannabis or phencyclic dine (PCP) are generally not aware of having developed tolerance (although it has been demonstrated in animal studies and in some individuals). Tolerance may be difficult to determine by history alone when the substance used is illegal and perhap mixed with various diluents or with other substances. In such situations, laborator tests may be helpful (e.g., high blood levels of the substance coupled with little evidence of intoxication suggest that tolerance is likely). Tolerance must also be distinguished from individual variability in the initial sensitivity to the effects of particula substances. For example, some first-time drinkers show very little evidence of intoxication with three or four drinks, whereas others of similar weight and drinking his tories have slurred speech and incoordination.

Withdrawal (Criterion 2a) is a maladaptive behavioral change, with physiologica and cognitive concomitants, that occurs when blood on tissue concentrations of a sub stance decline in an individual who had maintained prolonged heavy use of the sub stance. After developing unpleasant withdrawal symptoms, the person is likely to take the substance to relieve or to avoid those symptoms (Criterion 2b), typically us ing the substance throughout the day beginning soon after awakening. Withdrawa symptoms, which are generally the opposite of the acute effects of the substance, vari greatly across the classes of substances, and separate criteria sets for Withdrawal an provided for most of the classes. Marked and generally easily measured physiologi cal signs of withdrawal are common with alcohol, opioids, and sedatives, hypnotics and anxiolytics. Withdrawal signs and symptoms are often present, but may be les apparent, with stimulants such as amphetamines and cocaine, as well as with nicotine and cannabis. No significant withdrawal is seen even after repeated use of hallucino gens. Withdrawal from phencyclidine and related substances has not yet been de scribed in humans (although it has been demonstrated in animals). Neither tolerance nor withdrawal is necessary or sufficient for a diagnosis of Substance Dependence However, for most classes of substances, a past history of tolerance or withdrawal is associated with a more severe clinical course (i.e., an earlier onset of Dependence higher levels of substance intake, and a greater number of substance-related prob lems). Some individuals (e.g., those with Cannabis Dependence) show a pattern of compulsive use without obvious signs of tolerance or withdrawal. Conversely, some general medical and postsurgical patients without Opioid Dependence may develop a tolerance to prescribed opioids and experience withdrawal symptoms withou showing any signs of compulsive use. The specifiers With Physiological Dependence and Without Physiological Dependence are provided to indicate the presence or absence of tolerance or withdrawal.

The following items describe the pattern of compulsive substance use that is characteristic of Dependence. The individual may take the substance in larger amounts of over a longer period than was originally intended (e.g., continuing to drink until severely intoxicated despite having set a limit of only one drink) (Criterion 3). The individual may express a persistent desire to cut down or regulate substance use. Often there have been many unsuccessful efforts to decrease or discontinue use (Criterion 4)

ubstance Dependence

he individual may spend a great deal of time obtaining the substance, using the subtance, or recovering from its effects (Criterion 5). In some instances of Substance Deendence, virtually all of the person's daily activities revolve around the substance, mportant social, occupational, or recreational activities may be given up or reduced ecause of substance use (Criterion 6). The individual may withdraw from family activities and hobbies in order to use the substance in private or to spend more time with substance-using friends. Despite recognizing the contributing role of the substance to a psychological or physical problem (e.g., severe depressive symptoms or amage to organ systems), the person continues to use the substance (Criterion 7)-he key issue in evaluating this criterion is not the existence of the problem, but rather the individual's failure to abstain from using the substance despite having evilence of the difficulty it is causing.

pecifiers

'olerance and withdrawal may be associated with a higher risk for immediate generl medical problems and a higher relapse rate. Specifiers are provided to note their resence or absence:

With Physiological Dependence. This specifier should be used when Substance Dependence is accompanied by evidence of tolerance (Criterion 1) or withdrawal (Criterion 2).

Without Physiological Dependence. This specifier should be used when there is no evidence of tolerance (Criterion 1) or withdrawal (Criterion 2). In these individuals, Substance Dependence is characterized by a pattern of compulsive use (at least three items from Criteria 3–7).

Lourse Specifiers

six course specifiers are available for Substance Dependence. The four Remission pecifiers can be applied only after none of the criteria for Substance Dependence or substance Abuse have been present for at least 1 month. For those criteria that require ecurrent problems, a remission specifier can apply only if no aspect of the criterion ras been present (e.g., one incident of driving while intexicated would suffice to disqualify the individual from being considered in remission). The definition of these our types of Remission is based on the interval of time that has elapsed since the cessation of Dependence (Early versus Sustained Remission) and whether there is coninued presence of one or more of the items included in the criteria sets for Dependence or Abuse (Partial versus Full Remission). Because the first 12 months folowing Dependence is a time of particularly high risk for relapse, this period is desgreated Early Remission. After 12 months of Early Remission have passed without relapse to Dependence, the person enters into Sustained Remission. For both Early Remission and Sustained Remission, a further designation of Full is given if no criteria for Dependence or Abuse have been met during the period of remission; a designation of Partial is given if at least one of the criteria for Dependence or Abuse has been met, intermittently or continuously, during the period of remission. The differentiation of Sustained Full Remission from recovered (no current Substance Use Disorder) requires consideration of the length of time since the last period of disturbance, the total duration of the disturbance, and the need for continued evaluation. If, after a period of remission or recovery, the individual again becomes dependent, the application of the Early Remission specifier requires that there again be at least 1 month in which no criteria for Dependence or Abuse are met. Two additional specifiers have been provided: On Agonist Therapy and In a Controlled Environment. For an individual to qualify for Early Remission after cessation of agonist therapy or release from a controlled environment, there must be a 1-month period in which none of the criteria for Dependence or Abuse are met.

The following Remission specifiers can be applied only after no criteria for Dependence or Abuse have been met for at least 1 month. Note that these specifiers do not apply if the individual is on agonist therapy or in a controlled environment (see below).

Early Full Remission. This specifier is used if, for at least 1 month, but for less than 12 months, no criteria for Dependence or Abuse have been met.

Early Partial Remission. This specifier is used if, for at least 1 month, but less than 12 months, one or more criteria for Dependence or Abuse have been met (but the full criteria for Dependence have not been met).

Sustained Full Remission. This specifier is used if none of the criteria for Dependence or Abuse have been met at any time during a period of 12 months or longer.

Sustained Partial Remission. This specifier is used if full criteria for Dependence have not been met for a period of 12 months or longer; however, one or more criteria for Dependence or Abuse have been met.

```
r-Dependence → 1 → 11+ months — month
```

The following specifiers apply if the individual is on agonist therapy or in a controlled environment:

On Agonist Therapy. This specifier is used if the individual is on a prescribed agonist medication such as methadone and no criteria for Dependence or Abuse have been met for that class of medication for at least the past month (except tolerance to, or withdrawal from, the agonist). This category also applies to those being treated for Dependence using a partial agonist or an agonist/ antagonist.

In a Controlled Environment. This specifier is used if the individual is in an environment where access to alcohol and controlled substances is restricted, and no criteria for Dependence or Abuse have been met for at least the past month. Examples of these environments are closely supervised and substance-free jails, therapeutic communities, or locked hospital units.

Criteria for Substance Dependence

A maladaptive pattern of substance use, leading to clinically significant impairment or distress, as manifested by three (or more) of the following, occurring at any time in the same 12-month period:

- (1) talerance, as defined by either of the following:
 - (a) a need for markedly increased amounts of the substance to achieve intoxication or desired effect
 - (b) markedly diminished effect with continued use of the same amount of the substance
- (2) withdrawal, as manifested by either of the following:
 - (a) the characteristic withdrawal syndrome for the substance (refer to Criteria A and B of the criteria sets for Withdrawal from the specific substances)
 - (b) the same (or a closely related) substance is taken to refleve or avoid withdrawal symptoms.
- (3) the substance is often taken in larger amounts or over a longer period than was intended
- (4) there is a persistent desire or unsuccessful efforts to cut down or control substance use
- (5) a great deal of time is spent in activities necessary to obtain the substance (e.g., visiting multiple doctors or driving long distances), use the substance (e.g., chain-smoking), or recover from its effects
- (6) important social, occupational, or recreational activities are given up or reduced because of substance use
- (7) the substance use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance (e.g., current cocaine use despite recognition of cocaine-induced depression, or continued drinking despite recognition that an ulcer was made worse by alcohol consumption)

Criteria for Substance Dependence (continued)

Specify if:

With Physiological Dependence: evidence of tolerance or withdrawal (i.e., either Item 1 or 2 is present)

Without Physiological Dependence: no evidence of tolerance or withdrawal (i.e., meither Item 1 nor 2 is present)

Course specifiers (see text for definitions):

Early Full Remission
Early Partial Remission
Sustained Full Remission
Sustained Partial Remission
On Agonist Therapy
In a Controlled Environment

Substance Abuse

Features

The essential feature of Substance Abuse is a maladaptive pattern of substance use manifested by recurrent and significant adverse consequences related to the repeated use of substances. In order for an Abuse criterion to be met, the substance-related problem must have occurred repeatedly during the same 12-month period or been persistent. There may be repeated failure to fulfill major role obligations, repeated use in situations in which it is physically hazardous, multiple legal problems, and recurrent social and interpersonal problems (Criterion A). Unlike the criteria for Substance Dependence, the criteria for Substance Abuse do not include tolerance, withdrawal, or a pattern of compulsive use and instead include only the harmful consequences of repeated use, A diagnosis of Substance Abuse is preempted by the diagnosis of Substance Dependence if the individual's pattern of substance use has ever met the criteria for Dependence for that class of substances (Criterion B). Although a diagnosis of Substance Abuse is more likely in individuals who have only recently started taking the substance, some individuals continue to have substance-related adverse social consequences over a long period of time without developing evidence of Substance Dependence. The category of Substance Abuse does not apply to caffeine and nicotine. The term abuse should be applied only to a pattern of substance use that meets the criteria for this disorder; the term should not be used as a synonym for "use," "misuse," or "hazardous use."

The individual may repeatedly demonstrate intoxication or other substance-related symptoms when expected to fulfill major role obligations at work, school, or home (Criterion A1). There may be repeated absences or poor work performance related to recurrent hangovers. A student might have substance-related absences, suspensions, or expulsions from school. While intoxicated, the individual may neglect children or household duties. The person may repeatedly be intoxicated in situations that are

physically hazardous (e.g., while driving a car, operating machinery, or engaging in cisky recreational behavior such as swimming or rock climbing) (Criterion A2). There may be recurrent substance-related legal problems (e.g., arrests for disorderly conduct, assault and battery, driving under the influence) (Criterion A3). The person may continue to use the substance despite a history of undesirable persistent or recurrent social or interpersonal consequences (e.g., marital difficulties or divorce, verbal or physical fights) (Criterion A4).

Criteria for Substance Abuse

- A. A maladaptive pattern of substance use leading to clinically significant impairment or distress, as manifested by one (or more) of the following, occurring within a 12-month period:
 - (1) recurrent substance use resulting in a failure to fulfill major role obligations at work, school, or home (e.g., repeated absences or poor work performance related to substance use; substance-related absences, suspensions, or expulsions from school; neglect of children or household)
 - (2) recurrent substance use in situations in which it is physically hazardous (e.g., driving an automobile or operating a machine when impaired by substance use)
 - (3) recurrent substance-related legal problems (e.g., arrests for substance-related disorderly conduct)
 - (4) continued substance use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of the substance (e.g., arguments with spouse about consequences of intextication, physical fights)
- B. The symptoms have never met the criteria for Substance Dependence for this class of substance.

Substance-Induced Disorders

Substance Intoxication

Diagnostic Features

The essential feature of Substance Intoxication is the development of a reversible substance-specific syndrome due to the recent ingestion of (or exposure to) a substance (Criterion A). The clinically significant maladaptive behavioral or psychological changes associated with intoxication (e.g., belligerence, mood lability, cognitive impairment, impaired judgment, impaired social or occupational functioning) are due to the direct physiological effects of the substance on the central nervous system and develop during or shortly after use of the substance (Criterion B). The symptoms are not due to a general medical condition and are not better accounted for by another

mental disorder (Criterion C). Substance Intoxication is often associated with Su stance Abuse or Dependence. This category does not apply to nicotine. Evidence f recent intake of the substance can be obtained from the history, physical examinatic (e.g., smell of alcohol on the breath), or toxicological analysis of body fluids (e.g. urine or blood).

The most common changes involve disturbances of perception, wakefulness, a tention, thinking, judgment, psychomotor behavior, and interpersonal behavior. The specific clinical picture in Substance Intoxication varies dramatically among individuals and also depends on which substance is involved, the dose, the duration or chrinicity of dosing, the person's tolerance for the substance, the period of time since the last dose, the expectations of the person as to the substance's effects, and the environment or setting in which the substance is taken. Short-term or "acute" intoxication may have different signs and symptoms from sustained or "chronic" intoxication for example, moderate cocaine doses may initially produce gregariousness, be social withdrawal may develop if such doses are frequently repeated over days of weeks.

Different substances (sometimes even different substance classes) may product identical symptoms. For example, Amphetamine and Cocaine Intoxication can bot present with grandiosity and hyperactivity, accompanied by tachycardia, pupillar dilation, elevated blood pressure, and perspiration or chills. Also, alcohol and substances from the sedative, hypnotic, or anxiolytic class produce similar symptoms of intoxication.

When used in the physiological sense, the term intoxicution is broader than Sub stance Intoxication as defined here. Many substances may produce physiological o psychological changes that are not necessarily maladaptive. For example, an individ ual with tachycardia from excessive caffeine use has a physiological intoxication, bu if this is the only symptom in the absence of maladaptive behavior, the diagnosis of Caffeine Intoxication would not apply. The maladaptive nature of a substance induced change in behavior depends on the social and environmental context. The maladaptive behavior generally places the individual at significant risk for adverse effects (e.g., accidents, general medical complications, disruption in social and family relationships, vocational or financial difficulties, legal problems). Signs and symptoms of intoxication may sometimes persist for hours or days beyond the time when the substance is detectable in body fluids. This may be due to continuing low concentrations of the substance in certain areas of the brain or to a "hit and run" effect in which the substance alters a physiological process, the recovery of which takes longer than the time for elimination of the substance. These longer-term effects of intoxication must be distinguished from withdrawal (i.e., symptoms initiated by a decline in blood or tissue concentrations of a substance).

Criteria for Substance Intoxication

- A. The development of a reversible substance-specific syndrome due to recent ingestion of (or exposure to) a substance. **Note:** Different substances may produce similar or identical syndromes.
- B. Clinically significant maladaptive behavioral or psychological changes that are due to the effect of the substance on the central nervous system (e.g., beligerence, mood lability, cognitive impairment, impaired judgment, impaired social or occupational functioning) and develop during or shortly after use of the substance.
- C. The symptoms are not due to a general medical condition and are not better accounted for by another mental disorder.

Substance Withdrawal

Diagnostic Features

The essential feature of Substance Withdrawal is the development of a substancespecific maladaptive behavioral change, with physiological and cognitive concernitants, that is due to the cessation of, or reduction in, heavy and prolonged substance use (Criterion A). The substance-specific syndrome causes clinically significant distress or impairment in social, occupational, or other important areas of functioning (Criterion B). The symptoms are not due to a general medical condition and are not better accounted for by another mental disorder (Criterion C). Withdrawal is usually, but not always, associated with Substance Dependence (see p. 192). Most (perhaps all) individuals with Withdrawal have a craving to readminister the substance to reduce the symptoms. The diagnosis of Withdrawal is recognized for the following groups of substances; alcohol; amphetamines and other related substances; rocaine; nicotine; opioids; and sedatives, hypnotics, or anxiolytics. The signs and symptoms of Withdrawal vary according to the substance used, with most symptoms being the opposite of those observed in Intexication with the same substance. The dose and duration of use and other factors such as the presence or absence of additional illnesses also affect withdrawal symptoms. Withdrawal develops when doses are reduced or stopped, whereas signs and symptoms of Intoxication improve (gradually in some cases) after dosing stops.

Specify type: Labile Type/Disinhibited
Type/Aggressive Type/Apathetic
Type/Paranoid Type/Other Type/
Combined Type/Unspecified Type
293.9 Mental Disorder NOS
Due to ... [Indicate the General
Medical Condition] (190)

Substance-Related Disorders (191)

The following specifiers apply to Substance Dependence as noted:

^aWith Physiological Dependence/Without Physiological Dependence

bEarly Full Remission/Early Partial Remission/ Sustained Full Remission/Sustained Partial Remission

In a Controlled Environment

dOn Agonist Therapy

The following specifiers apply to Substance-Induced Disorders as noted:

With Onset During Intoxication/ With Onset During Withdrawal

ALCOHOL-RELATED DISORDERS (212)

Alcohol Use Disorders (213)

303,90 Alcohol Dependence^{a,b,c} (213) 305.00 Alcohol Abuse (214)

Alcohol-Induced Disorders (214)

303.00 Alcohol Intexication (214) 291.81 Alcohol Withdrawal (215)

Specify if: With Perceptual Disturbances
291.0 Alcohol Intoxication Delirium

291.0 Alcohol Withdrawal Delirium

291.2 Alcohol-Induced Persisting Dementia (168)

291.1 Alcohol-Induced Persisting Amnestic Disorder (177)

291.x	Alcohol-Induced	Psychotic
	Disorder (338)	Y 7 4 5

.5 With Delusions I,W

.3 With Hallucinations LW

291.89 Alcohol-Induced Mood Disorder^{I,W} (405)

291.89 Alcohol-Induced Anxiety Disorder^{t,W} (479)

291.89 Alcohol-Induced Sexual Dysfunction^I (562)

291.89 Alcohol-Induced Sleep Disorder^{I,W} (655)

291.9 Alcohol-Related Disorder NOS (223)

AMPHETAMINE (OR AMPHETAMINE-LIKE)-RELATED DISORDERS (223)

Amphetamine Use Disorders (224)

304.40 Amphetamine Dependence^{a,b,c}
(224)

305.70 Amphetamine Abuse (225)

Amphetamine-Induced Disorders (226)

292.89 Amphetamine Intexication
(226)
Specify if: With Perceptual Disturbances

292.0 Amphetamine Withdrawal (227)

292.81 Amphetamine Intoxication Delirium (143)

292.xx Amphetamine-Induced Psychotic Disorder (338)

.11 With Delusions^I

.12 With Hallucinations^I

292.84 Amphetamine-Induced Mood Disorder^{I,W} (405)

292.89 Amphetamine-Induced Arxiety
Disorder^I (479)

292.89 Amphetamine-Induced Sexual Dysfunction¹ (562)

292.89 Amphetamine-Induced Sleep Disorder^{I,W} (655)

292.9 Amphetamine-Related Disorder NOS (231)

SM-IV-TR Classification 292.84 Cocaine-Induced Mood AFFEINE-RELATED DISORDERS Disorder^{I,W} (405) 231) 292.89 Cocaine-Induced Anxiety Disorder^{LW} (479) Laffeine-Induced Disorders (232) Cocaine Induced Sexual 105.90 Caffeine Intoxication (232) 292.89 Dysfunction^I (562) 192.89 Caffeine-Induced Anxiety Cocaine-Induced Sleep Disorder (479) 292.89 Disorder^{I,W} (655) Caffeine-Induced Sleep 292.89 Cocaine-Related Disorder NOS Disorder (655) 292.9 Caffeine-Related Disorder NOS 292.9 (250)(234)HALLUCINOGEN-RELATED CANNABIS-RELATED DISORDERS DISORDERS (250) (234)Hallucinogen Use Disorders (251) 304.50 Hallucinogen Dependencebe Cannabis Use Disorders (236) 304.30 Cannabis Dependence^{a,b,c} (236) (251)305.30 Hallucinogen Abuse (252) 305.20 Carmabis Abuse (236) Hallucinogen-Induced Disorders Cannabis-Induced Disorders (237) 292.89 Cannabis Intexication (237) (252)292.89 Hallucinogen Intoxication (252) Specify & With Perceptual Disturbances 292.81 Carmabis Intoxication Delirium Hallucinogen Persisting 292.89 Perception Disorder 292 xx. Cannabis-Induced Psychotic (Flashbacks) (253) Hallucinogen Intoxication Disorder (338) 292.81 With Delusions Delirium (143) .11 With Hallucinations I 292 xx Hallucinogen-Induced 12 Psychotic Disorder (338) 292.89 Cannabis-Induced Anxiety With Delusions¹ Disorder (479) .11 With Hallucinations1 Cannabis-Related Disorder 292.9 .12 292.84 Hallucinogen-Induced Mood NOS (241) Disorder^I (405) COCAINE-RELATED DISORDERS 292.89 Hallucinogen-Induced Anxiety (241)Disorder¹ (479) Hallucinogen-Related Disorder Cocaine Use Disorders (242) 292.9 304.20 Cocaine Dependence^{a,b,c} (242) NOS (256) 305.60 Cocaine Abuse (243) INHALANT-RELATED DISORDERS Cocaine-Induced Disorders (244) (257)292.89 Cocaine Intoxication (244) Inhalant Use Disorders (258) Specify if: With Perceptual Disturbances 304.60 Inhalant Dependence^{b,c} (258) Cocaine Withdrawal (245) 292.0 305.90 Inhalant Abuse (259) 292.81 Cocaine Intoxication Delirium Inhalant-Induced Disorders (259) (143)292.89 Inhalant Intoxication (259) 292.xx Cocaine-Induced Psychotic 292.81 Inhalant Intoxication Delirium Disorder (338) With Delusions .11 (143)With Hallucinations1

.12

292.82	Dementia (168)		CYCLIDINE (OR CYCLIDINE-LIKE)-RELATED
292,x		DISO	RDERS (278)
	Disorder (338)	Phen	cyclidine Use Disorders (279)
.13			Phencyclidine Dependenceb,c
	With Hallucinations ¹		(279)
292.84		305.90	Phencyclidine Abuse (279)
	Disorder ^L (405)		cyclidine-Induced Disorders
292.89		(280)	cycliame-maacea Disorders
	Disorder ^I (479)	292.89	Phencyclidine Intoxication (280
292.9	Inhalant-Related Disorder NOS	E. 7 E. C. 7	Specify if: With Perceptual Disturbances
	(263)	292.81	Phencyclidine Intoxication
NICO:	TINE-RELATED DISORDERS		Delirium (143)
(264)		292.xx	
		23 21/61	Psychotic Disorder (338)
	ine Use Disorder (264)	.11	- ·
305.1	Nicotine Dependence ^{a,b} (264)	.12	•
Nicot	ine-Induced Disorder (265)		Phencyclidine-Induced Mood
292.0	Nicotine Withdrawal (265)		Disorder (405)
292.9	Nicotine-Related Disorder NOS	292.89	Phencyclidine-Induced Anxiety
	(269)	21	Disorder ¹ (479)
00101		292.9	Phencyclidine-Related Disorder
OPIO	D-RELATED DISORDERS (269)		NOS (283)
Opioi	d Use Disorders (270)	cenas	
304.00	Opioid Dependence ^{a,b,c,d} (270)		TIVE-, HYPNOTIC-, OR DLYTIC-RELATED DISORDERS
305.50	Opioid Abuse (271)		ILTRIC-RELATED DISORDERS
Onioi	d-Induced Disorders (271)	(284)	
	Opioid Intoxication (271)		ive, Hypnotic, or Anxiolytic
272.07	Specify if: With Perceptual Disturbances		sorders (285)
292.0	Opioid Withdrawal (272)	304.10	Sedative, Hypnotic, or
292.81	Opioid Intoxication Delirium		Anxiolytic Dependenceabe
	(143)		(285)
292.xx	Opioid-Induced Psychotic	305.40	Sedative, Hypnotic, or
			Americalistic Abusea (286)
	42E01@C1.3581		Anxiolytic Abuse (286)
.11	Disorder (338) With Delusions ^I	Sedati	ve-, Hypnotic-, or
.11	With Delusions ¹		
.12	With Delusions ^I With Hallucinations ^I		ve-, Hypnotic-, or
.12	With Delusions ^I With Hallucinations ^I Opioid-Induced Mood	Anxio	ve-, Hypnotic-, or lytic-Induced Disorders (286)
.12 292.84	With Delusions ^I With Hallucinations ^I Opiöid-Induced Mood Disorder ^I (405)	Anxio	ve-, Hypnotic-, or lytic-Induced Disorders (286) Sedative, Hypnotic, or
.12 292.84	With Delusions ^I With Hallucinations ^I Opioid-Induced Mood Disorder ^I (405) Opioid-Induced Sexual	Anxio 292.89	ve-, Hypnotic-, or lytic-Induced Disorders (286) Sedative, Hypnotic, or Anxiolytic Intoxication (286)
.12 292.84 292.89	With Delusions ^I With Hallucinations ^I Opioid-Induced Mood Disorder ^I (405) Opioid-Induced Sexual Dysfunction ^I (562)	Anxio 292.89	ve-, Hypnotic-, or lytic-Induced Disorders (286) Sedative, Hypnotic, or Anxiolytic Intoxication (286) Sedative, Hypnotic, or
.12 292.84	With Delusions ^I With Hallucinations ^I Opioid-Induced Mood Disorder ^I (405) Opioid-Induced Sexual Dysfunction ^I (562) Opioid-Induced Sleep	Anxio 292.89	ve-, Hypnotic-, or lytic-Induced Disorders (286) Sedative, Hypnotic, or Anxiolytic Intoxication (286) Sedative, Hypnotic, or Anxiolytic Withdrawal (287) Specify if: With Perceptual Disturbances Sedative, Hypnotic, or
.12 292.84 292.89 292.89	With Delusions ^I With Hallucinations ^I Opioid-Induced Mood Disorder ^I (405) Opioid-Induced Sexual Dysfunction ^I (562) Opioid-Induced Sleep Disorder ^{I,W} (655)	Anxio 292,89 292.0	ve-, Hypnotic-, or lytic-Induced Disorders (286) Sedative, Hypnotic, or Anxiolytic Intoxication (286) Sedative, Hypnotic, or Anxiolytic Withdrawal (287) Specify if: With Perceptual Disturbances Sedative, Hypnotic, or Anxiolytic Intoxication
.12 292.84 292.89	With Delusions ^I With Hallucinations ^I Opioid-Induced Mood Disorder ^I (405) Opioid-Induced Sexual Dysfunction ^I (562) Opioid-Induced Sleep Disorder ^{I,W} (655) Opioid-Related Disorder NOS	Anxio 292,89 292.0	Ve-, Hypnotic-, or lytic-Induced Disorders (286) Sedative, Hypnotic, or Anxiolytic Intexication (286) Sedative, Hypnotic, or Anxiolytic Withdrawal (287) Specify if: With Perceptual Disturbances Sedative, Hypnotic, or Anxiolytic Intexication Delirium (143)
.12 292.84 292.89 292.89	With Delusions ^I With Hallucinations ^I Opioid-Induced Mood Disorder ^I (405) Opioid-Induced Sexual Dysfunction ^I (562) Opioid-Induced Sleep Disorder ^{I,W} (655)	Anxio 292,89 292.0	Ve-, Hypnotic-, or lytic-Induced Disorders (286) Sedative, Hypnotic, or Anxiolytic Intexication (286) Sedative, Hypnotic, or Anxiolytic Withdrawal (287) Specify if: With Perceptual Disturbances Sedative, Hypnotic, or Anxiolytic Intexication Delirium (143) Sedative, Hypnotic, or
.12 292.84 292.89 292.89	With Delusions ^I With Hallucinations ^I Opioid-Induced Mood Disorder ^I (405) Opioid-Induced Sexual Dysfunction ^I (562) Opioid-Induced Sleep Disorder ^{I,W} (655) Opioid-Related Disorder NOS	292.89 292.0 292.81	ve-, Hypnotic-, or lytic-Induced Disorders (286) Sedative, Hypnotic, or Anxiolytic Intexication (286) Sedative, Hypnotic, or Anxiolytic Withdrawal (287) Specify if: With Perceptual Disturbances Sedative, Hypnotic, or Anxiolytic Intexication Delirium (143)

SM-IV-TR Classification

92.82	Sedative-, Hypnotic-, or
	Anxiolytic-Induced Persisting
	Dementia (168)

- 12.83 Sedative-, Hypnotic-, or Anxiolytic-Induced Persisting Amnestic Disorder (177)
- 32.xx Sedative-, Hypnotic-, or Anxiolytic-Induced Psychotic Disorder (338)
 - .11 With Delusions LW
- .12 With Hallucinations I,W
- 92.84 Sedative-, Hypnotic-, or Anxiolytic-Induced Mood-Disorder LW (405)
- 92.89 Sedative-, Hypnotic-, or Anxiolytic-Induced Anxiety Disorder W (479)
- 92.89 Sedative-, Hypnotic-, or Anxiolytic-Induced Sexual Dysfunction¹ (562)
- 92.89 Sedative-, Hypnotic-, or Anxiolytic-Induced Sleep Disorder^{1,W} (655)
- 92.9 Scdative-, Hypnotic-, or Anxiolytic-Related Disorder NOS (293)

OLYSUBSTANCE-RELATED DISORDER (293)

04.80 Polysubstance Dependence^{a,b,c,d} (293)

THER (OR UNKNOWN) UBSTANCE-RELATED DISORDERS

294)

Other (or Unknown) Substance Use Disorders (295)

- 04,90 Other (or Unknown) Substance Dependence^{a,b,c,d} (192)
- 05.90 Other (or Unknown) Substance Abuse (198)

Other (or Unknown) Substancenduced Disorders (295)

192.89 Other (or Unknown) Substance
Intoxication (199)
Specify if: With Perceptual Disturbances

292.0 Other (or Unknown) Stibstance Withdrawal (201) Specify if With Perceptual Disturbances

292.81 Other (or Unknown)
Substance-Induced Delirium
(143)

292.82 Other (or Unknown)
Substance-Induced Persisting
Dementia (168)

292.83 Other (or Unknown)
Substance-Induced Persisting
Ammestic Disorder (177)

292.xx Other (or Unknown)
Substance-Induced Psychotic
Disorder (338)

.11 With Delusions I.W

.12 With Hallucinations LW

292.84 Other (or Unknown)
Substance-Induced Mood
Disorder^{I,W} (405)

292.89 Other (or Unknown)
Substance-Induced Anxiety
Disorder^{I,W} (479)

292.89 Other (or Unknown)
Substance-Induced Sexual
Dysfunction (562)

292.89 Other (or Unknown) Substance-Induced Sleep Disorder^{I,W} (655)

292.9 Other (or Unknown)
Substance-Related Disorder
NOS (295)

Schizophrenia and Other Psychotic Disorders (297)

295.xx Schizophrenia (298)
The following Classification of Longitudinal
Course applies to all subtypes of
Schizophrenia:

Episodic With Interepisode Residual
Symptoms (specify if: With Prominent
Negative Symptoms)/Episodic With No
Interepisode Residual Symptoms